These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 8874844)

  • 1. TRH stimulation and dexamethasone suppression in borderline personality disorder.
    De la Fuente JM; Mendlewicz J
    Biol Psychiatry; 1996 Sep; 40(5):412-8. PubMed ID: 8874844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quality of depression in borderline personality disorder and the diagnostic process.
    Silk KR
    J Pers Disord; 2010 Feb; 24(1):25-37. PubMed ID: 20205497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine abnormalities in affective disorders.
    Extein I; Pottash AL; Gold MS
    Encephale; 1982; 8(2):203-11. PubMed ID: 6809445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression.
    Rush AJ; Giles DE; Schlesser MA; Orsulak PJ; Weissenburger JE; Fulton CL; Fairchild CJ; Roffwarg HP
    Biol Psychiatry; 1997 May; 41(9):915-28. PubMed ID: 9110097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone suppression test in borderline personality disorder--effects of posttraumatic stress disorder.
    Lange W; Wulff H; Berea C; Beblo T; Saavedra AS; Mensebach C; Wingenfeld K; Driessen M
    Psychoneuroendocrinology; 2005 Oct; 30(9):919-23. PubMed ID: 15896918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the biological nature of depressive symptoms in borderline patients without concomitant Axis I pathology idiosyncratic? Sleep EEG comparison with recurrent brief, major depression and control subjects.
    De la Fuente JM; Bobes J; Morlán I; Bascarán MT; Vizuete C; Linkowski P; Mendlewicz J
    Psychiatry Res; 2004 Nov; 129(1):65-73. PubMed ID: 15572186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the suicidal behavior of adolescent inpatients with borderline personality disorder and major depression.
    Horesh N; Orbach I; Gothelf D; Efrati M; Apter A
    J Nerv Ment Dis; 2003 Sep; 191(9):582-8. PubMed ID: 14504567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological nature of depressive symptoms in borderline personality disorder: endocrine comparison to recurrent brief and major depression.
    De la Fuente JM; Bobes J; Vizuete C; Mendlewicz J
    J Psychiatr Res; 2002; 36(3):137-45. PubMed ID: 11886691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borderline personality disorder characteristics in young adults with recurrent mood disorders: a comparison of bipolar and unipolar depression.
    Smith DJ; Muir WJ; Blackwood DH
    J Affect Disord; 2005 Jul; 87(1):17-23. PubMed ID: 15967232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse.
    Targum SD
    Biol Psychiatry; 1984 Mar; 19(3):305-18. PubMed ID: 6426529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of biologic markers in a general hospital affective disorders program.
    Lieber AL; Newbury N
    J Clin Psychiatry; 1985 Jun; 46(6):217-21. PubMed ID: 3922959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone suppression test and Axis I diagnoses of inpatients with DSM-III borderline personality disorder.
    Baxter L; Edell W; Gerner R; Fairbanks L; Gwirtsman H
    J Clin Psychiatry; 1984 Apr; 45(4):150-3. PubMed ID: 6715286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relation between results of thyrotropin-releasing hormone stimulation tests (TRH-ST), dexamethasone suppression test (DST) and urinary MHPG. SO4 excretion in depressive patients].
    Chen G
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Aug; 24(4):203-6, 251. PubMed ID: 1954790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amygdala volume and depressive symptoms in patients with borderline personality disorder.
    Zetzsche T; Frodl T; Preuss UW; Schmitt G; Seifert D; Leinsinger G; Born C; Reiser M; Möller HJ; Meisenzahl EM
    Biol Psychiatry; 2006 Aug; 60(3):302-10. PubMed ID: 16476409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships among the TRH, REM latency, and dexamethasone suppression tests: preliminary findings.
    Rush AJ; Schlesser MA; Roffwarg HP; Giles DE; Orsulak PJ; Fairchild C
    J Clin Psychiatry; 1983 Aug; 44(8 Pt 2):23-9. PubMed ID: 6409892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heightened subjective experience of depression in borderline personality disorder.
    Stanley B; Wilson ST
    J Pers Disord; 2006 Aug; 20(4):307-18. PubMed ID: 16901256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-lethality status in patients with borderline personality disorder.
    Soloff PH; Fabio A; Kelly TM; Malone KM; Mann JJ
    J Pers Disord; 2005 Aug; 19(4):386-99. PubMed ID: 16178681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological markers in borderline personality disorder: new perspectives.
    Korzekwa M; Links P; Steiner M
    Can J Psychiatry; 1993 Feb; 38 Suppl 1():S11-5. PubMed ID: 8453532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic markers in borderline personality disorder: a review.
    Lahmeyer HW; Reynolds CF; Kupfer DJ; King R
    J Clin Psychiatry; 1989 Jun; 50(6):217-25. PubMed ID: 2498295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of serial neuroendocrine challenge studies in the management of depressive disorder.
    Targum SD
    Biol Psychiatry; 1983 Jan; 18(1):3-19. PubMed ID: 6403062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.